|
|
 |
January 3, 2007 |
Now Available: Download the podcast of Dr. Burke's video presentation
With biweekly and special edition newsletters, Musculoskeletal Report is the top online resource for staying abreast of the most current and clinically relevant information in the field of musculoskeletal disease and treatment.
MSK Report provides cutting-edge scientific updates through in-depth interviews, on-location coverage of medical meetings, expert-led panel discussions, and live newscasts. With an editorial board of internationally recognized thought leaders, MSK Report is positioned to provide unparalleled quality news reporting with the highest level of credibility.
MSK Video Report:
Treating Osteoporosis in the New Era: Examining the Function and Structure of Bone
Susan Burke, MD discusses new developments in the identification, prevention and treatment of osteoporosis...
CME News: Practice Tips: Using Color or Power Doppler Ultrasound in Rheumatology
Danish researchers have proposed settings for Doppler ultrasound (US) designed to improve detection of inflammation, visualized as hyperemia in locations such as the synovial membrane...
Autoimmunity: Step-Down Therapy With Steroids is Feasible and Effective in Early RA
Step-down therapy for early rheumatoid arthritis (RA) including oral prednisolone is not just feasible in daily practice, it is also more effective than a step-up regimen...
Autoimmunity: Experts Question Use of TNF Blockers for Sciatica Caused by Disc Herniation
The jury is still out on whether TNF-blockers have a role in treating sciatica induced by disc herniation...
BioPharm Business: Forest, Cypress Submit New Drug Application for Milnacipran for the Treatment of Fibromyalgia
Forest Laboratories, Inc and Cypress Bioscience, Inc announced that they have submitted a New Drug Application (NDA) to the US FDA for milnacipran, a unique dual-reuptake inhibitor being developed for the treatment of fibromyalgia syndrome (FMS)...
BioPharm Business: Galapagos to Collaborate With Lilly in OA and to Receive Milestone Payment of €7.5 Million in OA Alliance with GSK
Galapagos NV, an integrated drug discovery company with preclinical programs in bone and joint diseases, announced that it has entered into a global collaboration agreement with Eli Lilly and Co to develop a novel class of medicines with potential to stimulate bone formation for the treatment of osteoarthritis...